A Phase II Study of Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy

NCT05527912 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Double Express Diffuse Large B-cell Lymphoma

Interventions

DRUG: Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy

Sponsor

Sun Yat-sen University